EGFR and non-small cell lung carcinoma: Of course, the inherent limitations of case studies should be noticed, including the small sample size and lack of generalizability, etc. The potential variability in treatment response across diverse patient populations with different genetic and environmental backgrounds would also be considered, especially among these EGFR-mutated NSCLC patients.